United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Seagen

There's a reason why many investors own one or more pharmaceutical stocks. This is a $1.2 trillion industry that is essential to the quality of life for many people.

3 Pharmaceutical Stocks to Buy and Hold for the Long Haul

AT&T

High-yield dividend stocks can be powerful capital appreciation vehicles. Pfizer and AT&T stand out as two of the most compelling buys within this group right now.

2 High-Yield Dividend Stocks That Could Be Incredible Bargains

On August 1, Pfizer released its financial report for the second quarter of 2023, which showed mixed results. Pfizer's revenue for the second quarter of 2023 was $18.28 billion, down 24.7% from the previous quarter and 34.1% from the second quarter of 2022. However, we believe that sales of Pfizer's COVID-19 products bottomed out in Q2 and could now turn higher due to the rapid spread of a new variant of COVID-19 called EG.5.1.

Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave

Bristol-Myers

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Johnson & Johnson

Eli Lilly

Merck

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Pharma ETFs in Focus Post Q2 Earnings

Raytheon Technologies

Exxon Mobil

The Major Indexes are off to a great start through the first seven months, largely due to the run in Technology. In the past few weeks, we have seen the rally start to broaden out, which is creating more opportunities in other sectors. Today we will look at 3 undervalued dividend stocks that all appear to be trading at great valuations.

3 Undervalued Dividend Stocks To Buy In August 2023

Pfizer's non-COVID business grew in the second quarter. It has numerous potential blockbusters in the works.

Does Pfizer Stock Belong in a Dividend Portfolio?

Ford Motor Company

Perdoceo Education

Rio Tinto plc Sponsored

Teladoc

Vipshop Hlds

The allure of high-potential dirt-cheap stocks often tempts those looking for the next big win. This year has seen some market sectors skyrocket while others remain in the shadows, with untapped potential.

7 Dirt-Cheap Stocks to Buy in August

Amgen

It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.

These 10 medications are likely targets for Medicare price negotiations this fall

Chevron

Disney

General Motors

JPMorgan Chase & Co

Lockheed Martin

August started with a whimper, as the recent stock rally receded. After hitting an end-of-July $457 high, the SPDR S&P 500 ETF (NYSEARCA: SPY ) pared back its gains and fell about 2% with plenty of intraday volatility on the charts.

7 Blue-Chip Stocks to Buy at an All-Time Low in August

Airgain

Cal-Maine Foods

Centene

Jerash holdings (US) Inc

MaxLinear

Petco Health and Wellness

While it's tempting on many levels to ride the flavors of the week, investors seeking long-term growth should consider the best sleeper stocks to buy. These securities feature very little investor interest for whatever reason.

The 7 Best Sleeper Stocks to Buy in August

Moderna

Novavax

Healthcare continues to lag in the broader market. Year to date, the Standards and Practices (S&P) 500 Health Care index is down 2% versus a 17% gain in the benchmark S&P 500 index.

3 Healthcare Stocks to Sell in August Before They Crash and Burn

Pfizer's revenue in Q2 fell by 52% as demand for its COVID products nosedived. The company's earnings are just a fraction of what Pfizer generated a year ago.

Pfizer's Profits Plunge 77%: Is the Dividend Still Safe?

Brookfield Renewable Partners

Kraft Heinz

PepsiCo

Public Storage

Solaris Oilfield Infrastructure

Valero Energy

Investors buy dividend stocks for a few reasons. For one, they provide income via dividends that act as a bonus on top of capital appreciation over time.

7 Dividend Stocks to Buy for Income and Upside

Novo Nordisk

Boston Beer Company

Constellation Brands

Molson Coors Brewing

If weight-loss drugs become multibillion-dollar blockbusters, snack makers and beer companies could take a hit, analysts say.

For Dieters, Obesity Drugs Are a Magic Pill. These Stocks Could Lose.

It's worth noting that blue-chip stocks go through their own bull and bear phase. Nvidia (NASDAQ: NVDA ) was under-performing until October 2022.

3 Massively Undervalued Blue-Chip Stocks for High Total Returns

Alphabet

Lattice Semiconductor

Lululemon Athletica

STMicroelectronics NV ADR RegS

Google stock and LULU make this screen of Warren Buffett stocks based on the investing strategy of Berkshire Hathaway's CEO.

Warren Buffett Stocks: GOOGL, LULU And More Test Buy Zones

News for Pfizer Stock (PFE)